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Breast cancer receptor status and stage at
diagnosis in over 1,200 consecutive public
hospital patients in Soweto, South Africa: a case
series
Valerie A McCormack1*, Maureen Joffe2, Eunice van den Berg3, Nadine Broeze2, Isabel dos Santos Silva4,
Isabelle Romieu1, Judith S Jacobson5, Alfred I Neugut5, Joachim Schüz1 and Herbert Cubasch2
Abstract
Introduction: Estimates of the proportion of estrogen receptor negative (ERN) and triple-negative (TRN) breast
cancer from sub-Saharan Africa are variable and include high values. Large studies of receptor status conducted on
non-archival tissue are lacking from this region.
Methods: We identified 1218 consecutive women (91% black) diagnosed with invasive breast cancer from
2006–2012 at a public hospital in Soweto, South Africa. Immunohistochemistry based ER, progesterone receptor
(PR) and human epidermal factor 2 (HER2) receptors were assessed at diagnosis on pre-treatment biopsy
specimens. Mutually adjusted associations of receptor status with stage, age, and race were examined
using risk ratios (RRs). ER status was compared with age-stratified US Surveillance Epidemiology and End Results
program (SEER) data.
Results: 35% (95% confidence interval (CI): 32–38) of tumors were ERN, 47% (45–52) PRN, 26% (23–29) HER2P and
21% (18–23) TRN. Later stage tumors were more likely to be ERN and PRN (RRs 1.9 (1.1-2.9) and 2.0 (1.3-3.1) for
stage III vs. I) but were not strongly associated with HER2 status. Age was not strongly associated with ER or PR
status, but older women were less likely to have HER2P tumors (RR, 0.95 (0.92-0.99) per 5 years). During the study,
stage III + IV tumors decreased from 66% to 46%. In black women the percentage of ERN (37% (34–40)) and PRN
tumors (48% (45–52)) was higher than in non-black patients (22% (14–31) and 34% (25–44), respectively, P = 0.004
and P = 0.02), which remained after age and stage adjustment. Age-specific ERN proportions in black South African
women were similar to those of US black women, especially for women diagnosed over age 50.
Conclusion: Although a greater proportion of black than non-black South African women had ER-negative or TRN
breast cancer, in all racial groups in this study breast cancer was predominantly ER-positive and was being
diagnosed at earlier stages over time. These observations provide initial indications that late-stage aggressive breast
cancers may not be an inherent feature of the breast cancer burden across Africa.
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Introduction
Breast cancer receptor status, most commonly defined
by estrogen-receptor (ER), progesterone-receptor (PR),
and human epidermal growth factor receptor 2 (HER2)
status in the clinical setting, has major implications for
breast cancer prevention strategies and patient manage-
ment [1,2]. Studies of these markers in African women
with breast cancer in sub-Saharan Africa (SSA) have had
extremely variable findings; reported percentages of es-
trogen receptor negative (ERN) tumors range from 30%
to 40% [3-5] to >70% [6-9]; in comparison, correspond-
ing percentages in the United States are 35% in breast
cancer patients aged 40 and decline to 15% to 20% by
age 70, and are slightly higher in black than in white
American women [10]. In SSA, for example, in 75
Ghanaian breast cancer patients, 76% were (ERN) based
on receptor testing carried out on formalin-fixed
paraffin-embedded specimens obtained in Ghana and
transported to the United States for receptor assessment
[9]. Similarly, in 500 tumor blocks from Nigeria and
Senegal, half were triple negative [7]. At the other end of
the spectrum, 27% of tumors were ERN among 192
Nigerian breast cancer patients in a setting in which immu-
nohistochemistry (IHC) was routinely conducted prospec-
tively at diagnosis [3]. The latter study is consistent with
recent related results from breast cancers diagnosed in the
United States in African-born women, of which 30% of
tumors with known receptor status were ERN [11].
A well-known pitfall of ER testing is that results are
highly sensitive to biopsy-tissue fixation and processing
procedures. These factors have led to false negatives
worldwide, as highlighted in the Consensus Recommen-
dations on Estrogen Receptor Testing in Breast Cancer
by Immunohistochemistry [12]. Ideally, receptor status is
determined on biopsy specimens obtained before pre-
operative neoadjuvant chemotherapy, and IHC is con-
ducted within a short time-frame to avoid antigen
degradation [13]. Receptor-status data from some previ-
ous SSA studies may have been vulnerable to such biases
because of a lack of routine receptor testing conducted
at diagnosis. Additionally, if receptor status is deter-
mined from mastectomy tissue taken after neoadjuvant
chemotherapy, the tumor phenotype may have evolved
from its original status. Conversely, overall ERN propor-
tions may be relatively high because of the relatively
young population age-structure; ERN disease is more
common in younger cases.
Knowledge of the receptor-status distribution among
breast cancer patients in SSA is needed, given the un-
certainty present and to improve our understanding of
tumor biology, prevention targets, and prognosis. To
begin to meet this need, we analyzed unique data from a
large (>1,200) consecutive breast cancer case series from
a public setting in South Africa where receptor status,
including HER2, was routinely measured at diagnosis
on prechemotherapy biopsy specimens. We examined
breast cancer receptor status in relation to demo-
graphic and clinical characteristics and compared age-
stratified ER status in black South African women
with that in US white and black women. A formal assess-
ment of missing receptor status, and racial comparisons
between black, white, colored, and Asian South African
women were also performed.
Methods
Setting
The study was set at the Chris Hani Baragwanath Aca-
demic Hospital (CHBAH), a large tertiary referral public
hospital (about 3,200 beds) in Soweto, South Africa.
South Africa’s public health sector serves 80% of the
population. It has a hierarchical referral system; most
patients seen at tertiary care facilities are referred from
primary health care clinics and secondary referral hospi-
tals [14]. CHBAH serves a population concentrated
within approximately 50 km of the hospital, situated
south of Johannesburg, Gauteng Province. A specialized
breast clinic was initiated at CHBAH in 2000, for which
a small diagnostic/treatment fee (R40 ≈ $5) is waived if
patients have no means to pay. Most breast cancer pa-
tients are symptomatic on arrival, as the majority of
women have no access to any form of early-detection ef-
forts such as by screening mammography or routine
clinical breast examination; mammographic screening is
available only to patients with good private health insur-
ance coverage, and few such patients come to CHBAH
for diagnosis. Opportunistic screening on mammog-
raphy trucks occasionally occurs in Soweto (for example,
by PinkDrive since late 2012), but these services were
not operational during the period of case ascertainment.
Diagnostic workup in the breast clinic includes mam-
mography, cytology, histology, and immunohistoche-
mistry (IHC; ER, PR, and HER2- receptor testing). All
breast carcinomas are histologically confirmed. Treat-
ment available at CHBAH or at other tertiary hospitals
in the province is standard breast cancer care, including
surgery, chemotherapy, hormonal therapy, and radiation
therapy.
The present study includes all women diagnosed with
in situ or invasive incident breast cancer at CHBAH be-
tween 01 October 2006, when routine collection of stan-
dardized clinicopathologic data commenced, to 04 July
2012, when data were last extracted. Clinical information
and routine histology reports in patient files and elec-
tronic pathology reports were used to populate an elec-
tronic database that is kept up to date for use in clinical
practice. For the present analyses, we obtained an
extract of the database, including demographic and clin-
ical variables. Age at diagnosis and date of birth were
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reported by the patient. Race was recorded by the cli-
nician as “black,” “white,” “colored,” (that is, of mixed
race), “Asian,” or “other.” As per the South African Cen-
sus nomenclature and definitions, these categories refer
to peoples with common characteristics in terms of his-
tory and descent, especially prior to the 1994 political
changes in South Africa [15]. Clinical characteristics in-
cluded tumor size, lymph-node positivity, stage at diag-
nosis (primarily coded according to TNM and then
converted to Manchester staging), Scarff-Bloom Richard-
son grade (1, 2, and 3 for well, moderately, and poorly
differentiated, respectively), invasiveness, and hormone
receptor status (see below). A human immunodeficiency
virus (HIV) test was offered to women (enzyme-linked
immunosorbent assay (ELISA) method HIV test) at breast
cancer diagnosis. Survival and risk-factor data were not
routinely collected.
Immunohistochemistry
The breast clinic’s implemented guidelines include ob-
taining a core breast biopsy before primary chemother-
apy. ER, PR, and HER2 status were routinely measured
on these biopsies to inform optimal patient treatment.
In practice, >90% of receptor testing was conducted on
biopsy material, and the remainder, on mastectomy tis-
sue, but we did not have an indicator of specimen type
for individual patients, so we could not use it to perform
sensitivity analyses. If a patient underwent preoperative
primary chemotherapy, receptor status included here
refers to that before such initiation. Tissue biopsies were
transferred to an on-site laboratory which is run by the
National Health and Laboratory Service (NHLS) of South
Africa and is also part of the University Witswatersrand
School of Pathology. The NHLS laboratory maintains a
close liaison with the breast clinic, and a messenger service
ensures rapid delivery of specimens. Time to fixation was
<24 hours for biopsy samples and <48 hours for mastec-
tomy tissue. This fully computerized NHLS academic
laboratory is accredited by the South African National
Accreditation System (SANAS), which performs annual
quality-control checks. H&E staining of 3-μm tissue sec-
tions was first verified for sufficient numbers of invasive
cells and fixation quality. The fully automated immuno-
stainer Ventana Benchmark XT was used for measurement
of ER and PR levels (CONFIRM™ , Tucson, Arizona, US).
Staining intensity was scored as 0 (none), 1 (weak), 2
(moderate), or 3 (strong). For ER and PR scores, specimens
with <1% nuclei staining were considered negative (score
0), and those with weak (1% to 10%, score 1), moderate
(10% to 33%, score 2), and strong (>33%, score 3) staining
were classified as hormone-receptor positive, denoted ERP
and PRP respectively. HER2 was analyzed by using Ventana
(PATHWAY™). No, weak, or moderate HER2 staining
(scores 0, 1, 2) were considered HER2 negative (HER2N),
and staining intensity 3 as HER2 positive (HER2P), to
enable direct comparison with previous studies [3,16,17]. A
positive control sample was included in all batches. Breast
cancer subtypes were also classified as luminal A (ERP and/
or PRP, HER2N), luminal B (ERP and/or PRP, HER2P),
HER2-positive enriched (HER2P, ERN, and PRN), and
triple-negative (TRN: HER2N, ERN, and PRN), a previously
used classification [1,18]. The NHLS laboratory provides
the histopathology report to the breast clinic in electronic
format; the receptor-staining scores are then entered into
the patient database.
Comparisons with US SEER data
Although the receptor status of breast cancer patients in
other settings has no bearing on the management of
individual patients in South Africa, international popula-
tion-level comparisons are informative for the under-
standing of the wider breast cancer epidemiology. We
thus compared age-specific ERN percentages of CHBAH
breast cancer patients with those for white and black
women in the United States SEER database [19], without
making assumptions regarding genetic or other com-
monalities between the black populations of Soweto and
of the United States. We extracted the number of inva-
sive breast cancers diagnosed by ER status (positive,
negative, unknown), by 10-year age band, for US white
and US black women and for the periods 1992 through
1996 and 2004 through 2008 separately. These two pe-
riods correspond to less- and more-intensive mammo-
graphic screening, which affects the ERN%. ERN
percentages were calculated from those with known ER
status (73,022 and 190,695 white and 6,683 and 21,293
black women in the early and later periods, respectively).
Although absolute incidence rates cannot be calculated,
distributions of age at diagnosis can be compared between
subtypes, as CHBAH patients arise from the same under-
lying population at risk. Differences in these distributions
provide information on the ratios of age-specific inci-
dence rates (for example, dips arise from a slowing of
the age-related increases in incidence rates, such as
the Clemmesen's hook at the menopause) [20,21].
The study was approved by the University of the
Witwatersrand Human Research Ethics Committee (26/08/
2011, ref. M110803); the need for individual patient consent
was waived, as this was a retrospective record review, which
used de-identified data from routine clinical records.
Statistical analyses
We first analyzed woman-level and clinical factors as-
sociated with the risk of ERN, PRN, and HER2P tumors
separately. A generalized linear model for these three bi-
nomial responses was fitted, by using a log link function
for the linear predictor to obtain regression coefficients
that represented the log-risk ratio of the outcome. For
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analysis of associations with the four-category combined
subtypes (luminal A, B, HER2P-enriched, and TRN), we
fitted a multivariate logistic regression model to estimate
odds ratios of each subtype compared by using the more
common luminal A tumors as the reference group.
Smoothed distributions of age at diagnosis were plotted
by using the Epanechnikov kernel function for density
estimation. All models were adjusted for age (<40, 40 to
49, 50 to 59, 60 to 69, 70 to 79, and ≥80 years) and year
at diagnosis (2006 to 2007, 2008 to 2009, 2010 to 2012)
by using indicator variables for categories. Age was also
fitted as a continuous variable (linear trend). These
models were first fitted by excluding women with miss-
ing receptor status or missing data on other variables on
a casewise basis. Given the possibility that “missingness”
on receptor status did not occur at random, and may
have influenced the overall percentages, the pattern of
missingness was examined in relation to age, stage, race,
and year at diagnosis by using a logistic regression
model and was used to generate 10 imputed values if
missing [22]. All analyses were conducted by using
STATA version 11.2.
Results
Over a period of 5 years 9 months, 1,247 breast cancers
were diagnosed: 12 (1.0%) in men, and 19 (1.5%) carcin-
oma in situ in women (all were DCIS) were excluded
hereafter (Table 1). The present analyses are restricted
to the 1,216 women with invasive breast cancer, of
whom 90% were black South African women, and the
remaining 10% were white, colored, or Asian. Mean age at
diagnosis was 55.3 years (standard deviation (SD) 14.3).
Of the patients, 23% were diagnosed at stage I/IIA, 24% at
stage IIB, and more than half (54%) at stages III/IV. About
89% were moderately/poorly differentiated (grade 2/3)
tumors. Clinical notes mentioned ductal carcinoma for
80% of women, lobular in 4.2%, medullary/mucinous in
3.0%, inflammatory in 1.6%, papillary in 2.3%, and Paget
disease for 0.6% (data not in tables).
Crude known and unknown receptor status
Among patients with known receptor status, 35% (95%
CI, 32 to 38) of tumors were ERN, 47% (44 to 50) PRN,
and 26% (23 to 29) HER2P (Table 1). High concordance
(82.2%) was found between ER and PR status: percentages
jointly classified were ERP and PRP 50.2%, ERP and PRN,
14.9%, ERN and PRP 2.9% and ERN and PRN 32.0%; thus
68% of tumors were hormone receptor positive (ERP and/
or PRP). ER, PR, and HER2 status were each missing
for between 10% and 15% of women. Missing receptor
status and tumor grade tended to occur in the same
women (see Additional file 1, Table S1). Receptor status
was missing in a nonrandom fashion with respect to
other variables (shown for ER status in Additional file 1,
Table S1, and is similar but not shown for PR and HER2).
Women with later-stage tumors had twice as many
missing ER scores than did women with earlier-stage I/II
tumors. Some suggestion was noted that breast cancers
diagnosed at younger than age 40 or older than age 80
had a higher proportion of missing ER status than did pa-
tients aged 40 to 80, but the difference was not statisti-
cally significant. After imputing missing values, the
overall ERN was 35.5% (n = 1,192) which was very close
to 35.3% in observed data (n = 1,063). Similarly, PRN per-
centages were 47.2% in observed and 47.3 in imputed
data: 26.0% for both observed and imputed HER2P. All
further results are based on observed data.
Receptor status, grade, and stage
ER, PR, and HER2 distributions are shown in Table 2,
and both crude and adjusted risk ratios for an ERN,
PRN, and HER2P tumor associated with other clinical
characteristics are provided in Table 3. The greatest
ERN and PRN differences occurred with tumor grade: a
fourfold greater risk of the tumor being ERN existed if it
was grade 3 compared with grade 1 (Table 3). Higher
grade was also, but less strongly, associated with an in-
creased risk of HER2P status. Similar to tumor grade,
stage III and IV tumors were almost 2 times more likely
to be ERN and PRN, but stage was less strongly associ-
ated with HER2 status (Table 2). Consequently, both
higher grade and later stage were strongly associated
with the combined subtype. HER2P-enriched (66%) and
58% of TRNs were diagnosed at stages III/IV compared
with 47% of luminal A tumors. Both HER2P-enriched
and TRN subtypes had >60% grade 3 tumors, compared
with 28% of luminal A.
Time trends
A time-trend of a declining proportion of ERN tumors
was accounted for by the trend of earlier stage at pre-
sentation over time. From 2006–2007 to 2010–2012, the
percentage of tumors diagnosed at stages III/IV declined
from 66% to 46% (Figure 1) and the percentage of poorly
differentiated tumors decreased from 55% to 35%. The
trend of earlier presentation did not differ by age, race,
or subtype (data not shown).
Race
After adjusting for age, year, and stage, nonblack women
had a 39% lower risk of having an ERN tumor, a 29%
lower risk of a PRN tumor compared with black patients,
but no significant difference in HER2 status (Table 3).
Compared with 11% of tumors that were HER2P enriched
and 20% TRNs in black breast cancer patients, corre-
sponding values were 5% and 13% in white, 8% and 10%
in colored, and 5% and 16% in Asian women (Table 2).
After adjusting for age and stage, nonblack women had
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Table 1 Characteristics of incident breast cancers diagnosed during October 2006 through July 2012 at Chris Hani
Baragwanath Academic Hospital Breast Clinic, Soweto, South Africa
Characteristic Variable completeness (%) Category No. (column % among nonmissing data)
Among all incident breast cancers (N = 1247)
Sex 100 Male 12 (1.0)
Female 1232 (99.0)
Invasiveness in women 100 Non-invasive 19 (1.5)
Invasive 1216 (98.5)
Among invasive incident breast cancers in women (N = 1216)
Ethnicity 99.4 Black 1,092 (90.3)
White 49 (4.1)
Colored 46 (3.8)
Asian 22 (1.8)
Age at diagnosis (years) <40 182 (15.0)
40–49 290 (23.9)
50–59 310 (25.5)
60–69 221 (18.2)
70–79 147 (12.1)
≥80 66 (5.4)
Year of diagnosis 100 2006–2007 172 (14.1)
2008–2009 431 (35.4)
2010–2012 613 (50.4)
HIV status 69.0 Negative 686 (81.8)
Positive 153 (18.2)
Stage 98.1 I 61 (5.1)
IIA 211 (17.7)
IIB 280 (23.5)
IIIA 148 (12.4)
IIIB-IIIC 385 (32.3)
IV metastases 107 (9.0)
Tumor grade 80.0 1 = Well-differentiated 106 (10.9)
2 = Moderately-differentiated 455 (46.8)
3 = Poorly-differentiated 412 (42.3)
ER 88.2 Negative 376 (35.1)
Positive: of which 696 (64.9)
Positive stain score +1 96
+2 155
+3 445
PR 87.8 Negative 500 (46.9)
Positive, of which: 567 (53.1)
Positive staining score +1 111
+2 163
+3 293
HER2 84.9 Negative, of which: 762 (74.1)
Negative stain score 0 404
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approximately half the odds of a HER2 tumor compared
with having a luminal A tumor (OR, 0.40 (0.17 to 0.96)
and half the odds of a TRN tumor (OR, 0.47, 0.24 to 0.89)
than did black women (Table 4). These differences were
also present before adjustment for age and stage, because
nonblack and black women did not differ in age at diagno-
sis (mean ages, 54.1 years (SD, 13.3) and 55.3 (SD, 14.6)
respectively, P = 0.36) and stage at diagnosis (percentages
diagnosed at stages I/II, III, and IV being 47.0, 42.7,
and 10.3 in nonblack and 46.4, 45.1, and 8.5 in black
women; P = 0.74).
Age
Age-at-diagnosis distributions by subtype are shown in
Figure 2 among black patients. ERP, PRP, and HER2P tu-
mors all had peak incidences in the middle to late forties
and a slight dip in the mid-fifties, indicating deceleration
of the rate of increase of the underlying incidence rates.
A dome-shaped distribution was found for luminal A tu-
mors, and peaks followed by troughs for luminal B,
HER2P enriched, and TRNs. Median age at diagnosis was
youngest for luminal B tumors (49.6 years that is, >5 years
younger than for luminal A tumors (55.0 years)). HER2P
tumors were also diagnosed at younger ages than were
TRN tumors. These arise from the trend of older age asso-
ciated with a lower risk of being HER2P (Table 3), whereas
age was not strongly associated with ER or PR status.
Comparison with US SEER data
Figure 3 plots age-specific ERN percentages in CHBAH
black patients overlaid on those for US SEER black and
white women in an early (1992 to 1996) and recent
(2004 to 2008) period. The lack of a strong inverse trend
of ER negativity with age in the CHBAH data contrasts
with the age-related decline that has been observed in
the US in earlier and later periods. ERN percentages in
South Africa were more similar to those of white women
younger than 50 years, but at ages 50+, they coincide
with those of US black women (age-adjusted odds ratio
for ER negativity comparing black South African with
US black women older than age 50 were 1.05 (95% CI,
0.89 to 1.26) in the early and 1.12 (0.95 to 1.33) in later
periods.
The high proportion of HIV+ (17%) breast cancer pa-
tients did not influence any of the results presented (an
HIV focus is the subject of a separate article). Most HIV+
women had a simultaneous diagnosis of HIV and breast
cancer; thus they had not been taking antiretroviral medi-
cation prior to breast cancer diagnosis.
Discussion
In this large systematic study of breast cancer receptor
status measured at diagnosis in a South African public
hospital, we observed that (a) the majority (63%) of tu-
mors were ER positive in black breast cancer patients,
and triple-negatives constituted one fifth of tumors, that
is, an overall subtype distribution not excessively differ-
ent from that in the West, especially to that of US black
women older than 50; (b) black women were more likely
than nonblack women to have ERN or triple-negative
breast cancer, and PRN and HER2P proportions were
relatively high; (c) in the absence of any organized
screening program, a decline occurred in the proportion
of late-stage breast cancers in a population that pre-
viously had a very high proportion of late-stage presen-
tation, suggesting possibilities for downstaging in low-
resource settings. These combined observations indicate
that very late-stage aggressive tumors may not be inher-
ent features of the breast cancer burden throughout
SSA. They suggest that, combined with appropriate and
timely treatment, improvements in breast cancer sur-
vival rates may be realistic targets in this and compa-
rable settings.
Based on >1,000 receptor-characterized tumors, ER
positivity (65% overall and 63% in black women) in
South African breast cancer patients was consistent with
that of black American women older than 50 years and
very similar to a Nigerian study (65%), which was also
based on IHC at diagnosis, and to others in South
Africa and Sudan [3-5]. However, several African studies
have reported that fewer than 40% of tumors were ERP
[6-9,23]. One of the latter studies also observed that
Table 1 Characteristics of incident breast cancers diagnosed during October 2006 through July 2012 at Chris Hani
Baragwanath Academic Hospital Breast Clinic, Soweto, South Africa (Continued)
+1 142
+2 216
Positive (+3) 267 (26.0)
Subtypes abbreviations: 84.5 Luminal A (ERP and/or PRP, HER2N) 551 (53.7)
Luminal B (ERP and/or PRP, HER2P) 150 (14.6)
HER2P enriched (ERN, PRN, HER2P) 117 (11.04)
Triple negative (ERN, PRN, HER2N) 209 (20.4)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.
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Table 2 Distribution of ER, PR, HER2, and their combinations by woman and tumor characteristics
ER status PR status HER2 status ER, PR, and HER2 status
number of women
ER, PR, and HER2 status
row distribution (%)
Number
positive
Number
negative
% ER
negative
Number
positive
Number
negative
% PR
negative
Number
positive
Number
negative
% HER2
positive
Luminal
A
Luminal
B
HER2P-
enriched
TRN Luminal
A
Luminal
B
HER2P-
enriched
TRN
All women 688 375 35.3† 559 499 47.2† 756 265 26.0† 545 149 116 209 53.5 14.6 11.4 20.5
Age <40 100 54 35.1 84 71 45.8 102 48 32.0 77 29 19 25 51.3 19.3 12.7 16.7
40–49 177 85 32.4 148 113 43.3 173 77 30.8 128 47 30 45 51.2 18.8 12.0 18.0
50–59 149 121 44.8 107 162 60.2 199 59 22.9 123 28 31 75 47.9 10.9 12.1 29.2
60–69 134 58 30.2 106 83 43.9 141 42 23.0 109 22 20 31 59.9 12.1 11.0 17.0
70–79 90 41 31.3 82 49 37.4 96 31 24.4 74 19 12 22 58.3 15.0 9.5 17.3
≥80 38 16 29.6 32 21 39.6 45 8 15.1 34 4 4 11 64.2 7.6 7.6 20.8
Calendar
year
2006–
2007
86 60 41.1 72 72 50.0 87 37 29.8 66 16 21 21 53.2 12.9 16.9 16.9
2008–
2009
241 144 37.4 186 198 51.6 263 116 30.6 183 65 51 80 48.3 17.2 13.5 21.1
2010–
2012
361 171 32.1 301 229 43.2 406 112 21.6 296 68 44 108 57.4 13.2 8.5 20.9
Stage I 43 13 23.2 41 16 28.1 40 14 25.9 34 10 4 6 63.0 18.5 7.4 11.1
II 319 130 29.0 262 184 41.3 345 95 21.6 262 60 35 81 59.8 13.7 8.0 18.5
III 271 202 42.7 218 254 53.8 314 133 29.8 207 68 65 107 46.3 15.2 14.5 23.9
IV 55 30 35.3 38 45 54.2 57 23 28.8 42 11 12 15 52.5 13.8 15.0 18.8
Tumor
grade
1 89 12 11.9 76 25 24.8 84 15 15.2 76 12 3 8 76.7 12.1 3.0 8.1
2 331 109 24.8 278 161 36.7 332 96 22.4 276 60 36 55 64.6 14.1 8.4 12.9
3 189 207 52.3 148 246 62.4 264 125 32.1 138 61 64 125 35.6 15.7 16.5 32.2
Missing 79 47 37.3 57 67 54.0 76 29 27.6 55 16 13 21 52.4 15.2 12.4 20.0
Ethnicity Black 606 351 36.7 492 461 48.4 679 240 23.1 481 131 109 196 52.5 14.3 11.9 20.4
White 32 8 20.0 27 13 32.5 29 9 23.7 24 7 2 5 63.2 18.4 5.3 13.2
Colored 30 9 23.1 26 13 33.3 30 8 21.1 26 5 3 4 68.4 13.2 7.9 10.5
Asian 15 5 36.7 12 8 40.0 14 5 25.3 11 4 1 3 57.9 21.1 6.3 15.8
Note: Percentages are among women with known receptor status. Numbers missing are provided in Table 1.
†Percentages (95% confidences intervals) are 35.3 (32.4 to 38.2) for ERN, 47.2 (44.2 to 50.2) for PRN, and 26.0 (23.3 to 28.6) for HER2P.
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TRNs constituted >50% of tumors, compared with 20%
observed here.
Several factors may contribute to these differences, in-
cluding the age of breast cancer patients, stage at diag-
nosis, histopathologic methods, differential underlying
risk-factor distributions, and ERP and ERN incidence
rates and genetic heterogeneity across this vast contin-
ent. The average age at breast cancer diagnosis of 55
years in the present study is between 6 and 10 years
older than that in most previous studies of receptor sta-
tus from SSA [3,6-9] and may contribute to the lower
ERN proportion in our study, although ERP tumors
dominated even at premenopausal ages in Soweto. As
expected, more late-stage tumors were ERN, as such tu-
mors have more-aggressive growth, and tumor progres-
sion is associated with a loss of estrogen expression [24].
The latter factor may have also contributed to the lower
ERN proportion in our study than in other SSA studies,
as stage at diagnosis was earlier (54% stage III/IV in So-
weto versus >80% in other studies). As the study design
in a case series and incidence rates cannot be calculated,
the lower ERN proportion in Soweto than in some other
SSA settings may result from similar incidence rates of
ERN breast cancer, but a higher incidence rate of ERP
Table 3 Risk ratio for ERN, PRN, and HER2P breast cancer
Risk ratio of ERN breast cancer Risk ratio of PRN breast cancer Risk ratio of HER2P breast cancer
Factor Category Crude RR Adjusted RR Crude RR Adjusted RR Crude Adjusted RR
RR 95% CI RR 95% CI RR 95% CI
Age (years) <40 1.08 1.11 0.84, 1.45 1.06 1.06 0.85, 1.32 1.04 1.02 0.76, 1.38
40–49 (ref) 1 1 - 1 1 - 1 1 -
50–59 1.38 1.33 1.08, 1.65 1.39 1.37 1.16, 1.61 0.74 0.74 0.56, 0.99
60–69 0.93 0.92 0.70, 1.20 1.01 1.03 0.83, 1.26 0.75 0.75 0.54, 1.03
70–79 0.96 0.95 0.70, 1.29 0.86 0.87 0.67, 1.13 0.79 0.80 0.56, 1.15
≥80 0.91 0.89 0.57, 1.38 0.92 0.86 0.60, 1.23 0.49 0.49 0.25, 0.94
per 5 years 0.99 0.99 0.95, 1.02 0.99 0.99 0.97, 1.01 0.95 0.95 0.92, 0.99
Pt = 0.37 Pt = 0.27 pt = 0.01
Calendar year 2006–2007 1.10 1.05 0.84, 1.32 0.97 0.91 0.76, 1.08 0.97 0.94 0.69, 1.28
2008–2009 (ref) 1 1 - 1 1 - 1 1 -
2010–2012 0.86 0.84 0.71, 1.00 0.84 0.82 0.72, 0.94 0.71 0.70 0.56, 0.88
P = 0.03 Pt = 0.09 p = 0.01
Stage I (ref) 1 1 - 1 1 - 1 1 -
II 1.25 1.23 0.75, 2.02 1.47 1.55 1.00, 2.41 0.83 0.89 0.54, 1.44
III 1.84 1.76 1.08, 2.85 1.92 1.99 1.29, 3.09 1.15 1.22 0.76, 1.98
IV 1.52 1.48 0.85, 2.57 1.93 1.92 1.20, 3.07 1.11 1.19 0.67, 2.11
Pt = 0.001 Pt = 0.001 pt = 0.05
Tumor grade 1 (ref) 1 1 - 1 1 1 1 -
2 2.09 1.94 1.11, 3.37 1.48 1.42 0.99, 2.04 1.48 1.30 0.79, 2.15
3 4.40 3.95 2.30, 6.79 2.52 2.37 1.67, 3.36 2.12 1.80 1.10, 2.95
Missing 3.14 2.83 1.58, 5.04 2.18 1.96 1.34, 2.86 1.82 1.63 0.93, 2.86
p = 0.01
Ethnicity Black (ref) 1 1 - 1 1 - 1 1 -
Nonblacka 0.61 0.61 0.42, 0.89 0.71 0.73 0.55, 0.95 0.89 0.86 0.59, 1.25
P = 0.009 P = 0.02 p = 0.42
White 0.55 0.55 0.29, 1.01 0.67 0.69 0.44, 1.07 0.91 0.87 0.49, 1.55
Colored 0.63 0.63 0.35, 1.11 0.69 0.70 0.45, 1.09 0.81 0.77 0.41, 1.43
Asian 0.68 0.72 0.34,1.53 0.83 0.81 0.48, 1.38 1.01 0.99 0.47, 2.09
P = 0.08 P = 0.13 p = 0.86
Note: Analyses based on 1,063 women for ER, 1,058 for PR, and 1,021 for HER2. Adjusted RRs are adjusted for age, stage, year, and race, unless this is the variable
of interest. P values denote test of heterogeneity across categories; Pt denotes test of linear trend.
aNonblack women are the combined group of white, colored, and Asian women.
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disease in Soweto. Urban South African women are
more westernized than their counterparts elsewhere in
Africa (for example, smaller family size, greater use of
hormonal contraception) [25], which may have led to
real increases in incidence rates for ERP breast cancer
and thus to a larger total breast cancer burden with a
greater proportion of ERP cases. Differences in findings
within Africa may also have been influenced by speci-
men collection or storage conditions (detailed in the
introduction). Notably, the studies with IHC conducted
at diagnosis that are less affected by antigen degradation
have shown that ERP tumors predominate. Additionally,
nuclear-staining cutoffs in some historical studies were
10% or 11% [3,8], as per the guidelines at the time,
whereas 1% was used here. Applying the higher cutoff to
our data, the ERN percentage would have increased
from 35% to 43%. Determination of receptor-status rela-
tive frequencies in other African settings, including rural
populations, is needed. Furthermore, as no single out-
right majority subtype exists, receptor classification is
needed for clinical decision making, but is not always
available in SSA. That the majority of tumors in this
study were the better-prognosis ERP tumors is, mean-
while, an encouraging feature of this burden. Research is
needed into whether the more-favorable prognostic pro-
file in Sowetan breast cancer patients confers survival
gains.
Although the majority breast cancer burden in this
study was postmenopausal and ERP, nevertheless, one in
three tumors was poorer-prognosis HER2P enriched or
TRNs. The real HER2P percentage may be even higher,
as 26% of tumors had a 2+ IHC HER2 staining score,
and previous unpublished work at CHBAH comparing
IHC and FISH HER2 status found that 50% of IHC
HER2 2+ stains were FISH HER2P. Regardless of the
HER2 assessment method, the percentage of HER2P tu-
mors is higher than in several other reports in Africa
[3,7]. Thus, affordable treatment for HER2P tumors, by
trastuzumab or other agents, is needed in this setting.
Additionally, the proportion of tumors that were PRN
(48%) was higher than in US data today and before the
introduction of screening (33% to 39% PRN at age 50)
[26]. Reexamination of these proportions in Africa, and
an investigation of their drivers, are needed.
A predominance of better-prognosis luminal A and B
tumors and the strong downstaging trend over time
suggest that late stage at diagnosis in the South African
setting may be driven to a greater extent by nonbiologic
determinants of stage at diagnosis rather than by the
predominance of an inherent aggressive rapidly growing
tumor, but must be confirmed in other studies. Luminal
A and B tumors, both ERP tumors, have good 5-year
survival (about 90%) compared with <80% for HER2P
and TRN tumors in US settings [18]. Whether subtype-
specific tumors have different prognoses still must be in-
vestigated within African populations, but given the
downstaging trends observed in this South African setting,
the potential impact on lives saved can be estimated, as-
suming external stage-specific 5-year survival rates [27].
Of 1,000 women diagnosed with this improvement would
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Figure 1 Relative distribution of stage at diagnosis by year at diagnosis.
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result in an additional 80 women alive 5 years after diag-
nosis. The reasons for the observed downstaging are likely
to be multifactorial, including factors at both the individ-
ual and health-system levels (for example, improving pub-
lic awareness through media campaigns, faster referral,
and a dedicated tertiary hospital breast clinic that was in-
creasing in volume and ease of access). Importantly, these
trends occurred within a resource-limited setting and
without population-based screening, and demonstrate that
earlier presentation is achievable in similar settings.
Further research is needed to evaluate the relative
contributions to downstaging of all components of a
woman’s journey from first noticing symptoms to diag-
nosis at CHBAH.
Black women were more likely to have ERNnegative
tumors than were white, colored, or Asian South African
breast cancer patients. Despite wide confidence intervals,
the odds ratios for TRN, HER2P enriched, and luminal
B versus luminal A tumors for black versus nonblack
women were 2.0 (95% CI, 1.1 to 3.8), 2.2 (1.0 to 4.9), and
1.0 (0.6 to 1.8) (reciprocals of those already provided in
Table 4), estimates that are remarkably similar to those
found for African American versus non-African American
women in the Carolina Breast Cancer Study (ORs of 2.1,
1.8, and 0.9, respectively) [18]. Racial differences in the
South African study are unlikely to be due to differential
early detection by screening mammography because
women with medical aid coverage of screening mammo-
grams are unlikely to be directed to CHBAH for diagnosis.
Women with positive findings on screening mammog-
raphy are likely to remain within the private sector for
diagnostic workup and treatment. Indeed, all the women
for whom we had referral information had been referred
from a local health clinic or doctor, hospital, or were self-
referrals.
The age distributions for ERN and PRP tumors in
Soweto showed a dip in frequency distribution at age 60,
which corresponds to the Clemmesen hook and reflects
Table 4 Adjusted odds ratios for Luminal B, HER2+ enriched, and triple-negative tumors compared with having a
Luminal A tumor
Luminal B (n = 148) vs
Luminal A (n = 545)
HER2P enriched (n = 116) vs
Luminal A (n = 545)
Triple negative (n = 209) vs
Luminal A (n = 545)
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Age (years) <40 1.04 (0.60, 1.79) 1.11 (0.58, 2.13) 0.94 (0.53, 1.65)
40–49 1 1 1
50–59 0.61 (0.36, 1.04) 1.08 (0.61, 1.91) 1.70 (1.09, 2.67)
60–69 0.54 (0.31, 0.96) 0.75 (0.40, 1.41) 0.78 (0.46, 1.33)
70–79 0.69 (0.38, 1.28) 0.69 (0.33, 1.46) 0.84 (0.47, 1.52)
≥80 0.30 (0.10, 0.91) 0.50 (0.16, 1.53) 0.84 (0.39, 1.81)
Ptrend = 0.003 Ptrend = 0.21 Ptrend = 0.33
Calendar year 2006–2007 1 1 1
2008–2009 1.57 (0.83, 2.91) 0.93 (0.51, 1.69) 1.35 (0.76, 2.39)
2010–2012 1.00 (0.54, 1.85) 0.49 (0.27, 0.89) 1.12 (0.64, 1.94)
Ptrend = 0.27 Ptrend = 0.003 Ptrend = 0.96
Stage I–II 1 1 1
III–IV 1.41 (0.98, 2.04) 2.34 (1.53, 3.59) 1.67 (1.20, 2.32)
Tumor grade 1 1 1 1
2 1.16 (0.59, 2.31) 2.54 (0.75, 8.59) 1.62 (0.73, 3.60)
3 2.35 (1.17, 4.73) 8.65 (2.59, 28.9) 7.70 (3.52, 16.8)
Missing 1.72 (0.74, 4.01) 4.61 (1.23, 17.26) 2.99 (1.21, 7.37)
Ethnicity Black 1 1 1
Nonblacka 0.95 (0.52, 1.71) 0.40 (0.17, 0.96) 0.47 (0.24, 0.89)
White 1.02 (0.42, 2.44) 0.34 (0.08, 1.49) 0.50 (0.19, 1.35)
Colored 0.70 (0.26, 1.91) 0.44 (0.13, 1.53) 0.36 (0.12, 1.07)
Asian 1.37 (0.41, 4.30) 0.41 (0.05, 3.27) 0.63 (0.17, 2.32)
Note: Odds ratios are adjusted for age, stage, year, and race, unless this is the variable of interest.
aNonblack women are the combined group of white, colored, and Asian women.
Owing to these suggestions of racial variations in ER status, subsequent Figures 2 and 3 were restricted to black women only (that is, the more homogeneous
group and population of main interest).
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Figure 2 Smoothed frequency distributions of age at breast cancer diagnosis in black South African women, by receptor status.
Figure 3 Age-specific percentages of breast tumors that are ER negative in black women in Soweto (2006–2012) and US black and
white breast cancer cases diagnosed during 1992–1996 and 2004–2008.
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a plateauing of incidence rates at postmenopausal ages
[20,21]. HER2P tumors also displayed this feature of a
younger age peak at age 50 and a dip at age 60; their age
distribution was virtually equivalent to quite a distinct
population (for example, in Hawaii [17]). However, dif-
ferences in age distributions by ER-receptor status were
not as pronounced as have been observed in high-risk
populations such as the United States (younger distribu-
tion for ERN tumors) [17,21]; thus ER proportions by
age would benefit from re-investigation in other large
breast cancer case series from Africa. Higher rates of
ERP cancers at older ages in the United States are likely
to account for this difference, because the major lifestyle
transitions (early menarche, low parity, late childbearing,
postmenopausal weight gain, less breastfeeding) are
stronger risk factors for ERP breast cancer, and screen-
ing is more likely to detect these tumors [28]. In US,
white and black women incidence rates of ERP breast
cancer have increased, whereas for ERN tumors, they
have decreased during the past 2 decades [10], driving
an increasing percentage of ERP cancers over time and
with age. In the same way, South Africa may be at an
earlier stage of a breast cancer transition that will see an
increasing rate of ERP disease as younger cohorts with
less-traditional reproductive profiles reach postmeno-
pausal ages.
This study is unique for this setting in terms of the
sample size, IHC performed at diagnosis on preche-
motherapy biospecimens in quality-controlled laborator-
ies, and inclusion of HER2 expression. Analytically, we
carefully assessed the influence of the 11% unknown re-
ceptor status; they were more likely to be ERN, as they
were advanced tumors. The study is essentially a
hospital-based case series, but it is likely to have fewer
problems of underdiagnosis and thus a skewed patient
profile that misrepresents the true population burden in
rural and in lower-resource settings. The case series is
likely to be representative of breast cancers in the public
health sector of Soweto, as CHBAH provides affordable
care and is easily accessible and known to the geogra-
phically close population (78% live within 25 km).
Conclusion
Although a greater proportion of black than nonblack
South African women had ERN or TRN breast cancer,
in all racial groups in this urban South African setting,
breast tumors were predominantly ERP. We observed a
strong trend of earlier stage at diagnosis over a 5–year
period. Further research is needed to assess subtype-
specific risk factors and subtype-specific survival in this
setting. These findings provide initial indications that
late-stage aggressive breast cancers may not be an inhe-
rent feature of the sub-Saharan African breast cancer
burden.
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